Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

LYEL

0.00

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ: LYEL) with a Buy and maintains $44 price target.